Skip to NavigationSkip to content

AstraZeneca's Imfinzi becomes India's first available immunotherapy for lung cancer

Published on 22/06/18 at 10:32am

In a big step forward for India as AstraZeneca announces that its checkpoint inhibitor Imfinzi (durvalumab) has secured approval in the country from the Drug Controller General of India (DCGI) to become the first available immunotherapy for the treatment of unresectable non-small cell lung cancer (NSCLC).

Imfinzi is a human monoclonal antibody which functions by binding to the PD-L1 protein, which tumours are known to use to evade attacks from the body’s immune system, and blocks its interaction with PD-1 and CD80. This latest approval follows the decision taken by the FDA in February this year to authorise the sale of the drug in the US in NSCLC after it demonstrated improvements in median progression-free survival of 11.2 months.

Approval in NSCLC is considered a considerable boost to the potential success of a cancer therapy, with the condition accounting for 85% of all lung cancer cases, which is itself one of the most common cancers. This is particularly important in India, where the disease is the most common cancer across the country in men and is responsible for more deaths than any other, at 13.7%.

“The import and market permission for durvalumab for unresectable stage III non-small cell lung cancer and locally advanced or metastatic urothelial carcinoma is a significant milestone for patients who have currently limited treatment options,” commented Gagan Singh, Managing Director at AstraZeneca Pharma India. “In India, approximately one third of patients with NSCLC are present with Stage III disease and we are excited to bring the first immunotherapy into this setting for patients.”

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches